Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Login to CNS Plus Login to CasePortal
Friday, April 19, 2024
Courthouse News Service
Free Litigation Reports Find Judicial Opinions
Friday, April 19, 2024 | Back issues
Courthouse News Service Courthouse News Service

Virus Outbreak Treatments

FILE - The Eli Lilly corporate headquarters is pictured April 26, 2017, in Indianapolis. A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday, Sept. 14, 2020, from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. (AP Photo/Darron Cummings, File)

/ September 14, 2020
FILE - The Eli Lilly corporate headquarters is pictured April 26, 2017, in Indianapolis. A drug company says that adding an anti-inflammatory medicine to a drug already widely used for hospitalized COVID-19 patients shortens their time to recovery by an additional day. Eli Lilly announced the results Monday, Sept. 14, 2020, from a 1,000-person study sponsored by the U.S. National Institute of Allergy and Infectious Diseases. (AP Photo/Darron Cummings, File)
Follow @bleonardcns
Categories /

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Additional Reads

Loading...